Anavex Life Sciences Corp.
AVXLNASDAQHealthcare● Active
$2.59
+$0.02(+0.78%)
Market Cap$240019853
P/E Ratio—
52W High$13.99
52W Low$2.54
Anavex Life Sciences Corp. (AVXL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AVXL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.04B | $0.04B | $0.04B | $0.04B | $0.03B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.05B | $0.05B | $0.06B | $0.05B | $0.04B |
| Operating Income | ($0.05B) | ($0.05B) | ($0.06B) | ($0.05B) | ($0.04B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.05B) | ($0.04B) | ($0.05B) | ($0.05B) | ($0.04B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.05B) | ($0.04B) | ($0.05B) | ($0.05B) | ($0.04B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.54 | $-0.52 | $-0.60 | $-0.62 | $-0.54 |
| Wtd Avg Shares | 0.09B | 0.08B | 0.08B | 0.08B | 0.07B |
| EBITDA | ($0.05B) | ($0.04B) | ($0.05B) | ($0.05B) | ($0.04B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Anavex Life Sciences Corp. data
About Anavex Life Sciences Corp. (AVXL) Income Statement
Anavex Life Sciences Corp. (AVXL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AVXL reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.05B) — a net profit margin of —.
Frequently asked questions
AVXL · 4 questionsAnavex Life Sciences Corp. (AVXL) reported revenue of $0.00B for 2025, down —% year-over-year.
AVXL revenueAVXL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08